UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 58

of 'Clinical course and management of monoclonal gammopathy of undetermined significance'

58
TI
Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1αlevels in patients with MGUS.
AU
Ng AC, Khosla S, Charatcharoenwitthaya N, Kumar SK, Achenbach SJ, Holets MF, McCready LK, Melton LJ 3rd, Kyle RA, Rajkumar SV, Drake MT
SO
Blood. 2011;118(25):6529. Epub 2011 Oct 31.
 
Recent population-based studies demonstrate an increased fracture risk with monoclonal gammopathy of undetermined significance (MGUS). The etiology of this increased risk remains unclear, however, because areal bone mineral density (aBMD) measurements by dual-energy x-ray absorptiometry cannot assess bone microstructural properties critical to determining bone quality and strength. To better define the skeletal effects of MGUS, we performed aBMD and high-resolution peripheral quantitative computed tomography volumetric bone mineral density (vBMD) measurements in 50 MGUS patients (20 females, 30 males; mean±SEM age, 70.5±1.4 years) and 100 matched control subjects. Relative to controls, MGUS patients had decreased aBMD at the femoral neck (P = .05) and total femur (P<.05) but no differences at other sites. In contrast, high-resolution peripheral quantitative computed tomography showed markedly diminished cortical thickness (P<.05) and increased endocortical area (P<.01). Average vBMD (P<.01), cortical vBMD (P<.001), and trabecular thickness (P<.01) were all significantly decreased in MGUS patients, suggestive of impaired bone formation. Serum levels of the Wnt pathwayinhibitor Dickkopf-related protein 1 (P<.001) and osteoclast-activating factor MIP-1α(P<.05) also were significantly elevated in MGUS patients. Our data provide the first evidence of altered bone microstructure in MGUS and suggest that cytokines elevated in osteolytic myeloma also may be associated with bone loss in MGUS.
AD
Division of Endocrinology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
PMID